Hypogammaglobulinemia in Heart Transplant Recipients Treated With Tacrolimus, Mycophenolate, and Prednisone

Avery, Robin K.; Mawhorter, Steven D.; Starling, Randall C.; McCarthy, Patrick; Smedira, Nicholas; Goormastic, Marlene; Pelegrin, D.; M, Majercík; Hobbs, Robert E.; Hoercher, Katherine J.; Cook, Dominique; Young, J B

doi:10.1097/00007890-199904150-00383

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although no conclusions can be drawn from this current report regarding causal relationships, it will be of interest to monitor various specific parameters of immune function in patients on newer immunosuppressive regimens. A prospective study is ongoing to study hypogammaglobulinemia in a larger group of heart transplant patients, and to attempt to correlate this with immunosuppressive regimens and clinical outcomes ( 23).…”

Section: Discussionmentioning

confidence: 96%

“…The sixth was receiving MMF, cyclosporine, and prednisone, but had also previously undergone total lymphoid irradiation and plasmapheresis for severe early vascular rejection. Whether or not the combination of tacrolimus and MMF represents a greater risk for hypogammaglobulinemia and for infection than other regimens, such as MMF in combination with cyclosporine, is the subject of an ongoing prospective study in heart transplant recipients ( 23).…”

Section: Six Heart Transplant Recipients With Igg Levels Below 310 Mgmentioning

confidence: 99%

See 1 more Smart Citation

Significant post‐transplant hypogammaglobulinemia in six heart transplant recipients: an emerging clinical phenomenon?

Corales¹,

Chua²,

Mawhorter³

et al. 2000

Transplant Infectious Dis

View full text Add to dashboard Cite

The finding of unexpected hypogammaglobulinemia and concomitant infectious complications in six heart transplant recipients highlights a possible complication in a subset of patients receiving newer immunosuppressive agents. A larger prospective study is underway to determine risk factors for development of post-transplant hypogammaglobulinemia and to assess pre-transplant immune status of these recipients. Monitoring of immunoglobulin levels in high-risk patients receiving intensified immunosuppressive therapy for rejection may help to prevent infectious complications.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Six Heart Transplant Recipients With Igg Levels Below 310 Mgmentioning

confidence: 99%